Journals / Anadolu Tıp Dergisi / 2001 / Cilt: 3 - Sayı: 1

Plasma and erythrocyte prolidase activity in patients with lung carcinoma

Akciğer karsinomlu hastalarda plazma ve eritrosit prolidaz aktivitesi

Pages
22–25
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The erythrocyte prolidase activity was lower in the patients; 28.4±2.3 U/gHb compared to the controls; 40.9±2.3U/gHb (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prolidase is a dipeptidase that takes part in recycling of proline for collagen synthesis and cell growth.
📊
Key Findings & Data:Elevation of prolidase activity was observed in G3-poorly differentiated lung adenocarcinomas, accompanied by an increase of tissue collagen content.
💡
Conclusion & Impact:The erythrocyte prolidase activity was lower in the patients; 28.4±2.3 U/gHb compared to the controls; 40.9±2.3U/gHb (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Prolidase is a dipeptidase that takes part in recycling of proline for collagen synthesis and cell growth. Elevation of prolidase activity was observed in G3-poorly differentiated lung adenocarcinomas, accompanied by an increase of tissue collagen content. In our previous study, increased erythrocyte prolidase activity was obtained in patients with lung carcinoma but its possible relation with tumor histology, clinical stage and plasma prolidase activity were not evaluated. In the present study, 19 male patients with lung carcinoma and 16 age and gender matched healthy subjects' plasma and erythrocyte prolidase activities were determined by Chinard method. The plasma prolidase activity(mean ± SEM) was 80.6±6.16U/dl in patients and 99.1±7.49 U/dl in the control group (p>0.05). The erythrocyte prolidase activity was lower in the patients; 28.4±2.3 U/gHb compared to the controls; 40.9±2.3U/gHb (p

Özet

Prolidaz (EC ,3.4.13.9) kollajen sentezi ve hücre büyümesinde kullanılan prolinin geri kazanılmasında rol alan bir dipeptidazdır. G3-kötü diferansiye akciğer adenokarsinomlarında doku prolidaz aktivitesi ve bunu izleyen doku kollajen içeriği artışı saptanmıştır. Önceki çalışmamızda akciğer karsinomlu hastalarda yüksek eritrosit prolidaz aktivitesi saptanmış ancak tümör histolojisi ve evresi ile ilişkisi ve serum prolidaz aktivitesi değerlendirilmemiştir. Çalışmamızda akciğer karsinomlu 19 erkek hasta ve benzer yaş ve cinsiyette 16 sağlıklı bireyin serum ve eritrosit prolidaz aktiviteleri Chinard yöntemi ile analiz edilmiştir. Serum prolidaz aktivitesi akciğer kanserli hastalarda; (ort$pm$SEM) 80.6+6.16 U/dl, kontrol grubunda; 99.1±7.49U/dl olarak saptanmıştır (p>0.05). Eritrosit prolidaz aktivitesi ise hasta grubunda; 28.4±2.3U/g Hb, kontrol grubundan; 40.9±2.3U/g Hb düşüktür (p

🔖

Cite This Article

TARAKÇIOĞLU, M., NAMIDURU, E. S., BAYRAM, N., ERBAĞCI, A. B. (2022). Plasma and erythrocyte prolidase activity in patients with lung carcinoma. Anadolu Tıp Dergisi, Cilt: 3 - Sayı: 1, 22–25. https://ajindex.com/articles/438174

References (12)

  1. Alparslan S, Gültepe M, Kılınç C, et al. Serum prolidase activity: Its value as an indicator of collagen accumulation in chronic liver diseases. Biyokimya Dergisi. 1993; 1:1-9
  2. Bissonnette R, Friedman D, Giroux JM, et al. Prolidase deficiency: A multisystemic hereditary disorder. J Am Acad Dermatol 1993;29:818-21
  3. Cosson C, Myara I, Miech G, et al. Only prolidase I activity is present in human plasma. Int JBiochem 1992;24:427-32
  4. Dolenga M, Hechtman P. Prolidase deficiency in cultured human fibroblasts: biochemical pathology and immunodipeptide-enhanced growth. Ped Res. 1992; 4:497-82
  5. Erbağcı AB, Özdemir Y. Erythrocyte prolidase activityin patients with non-hematological malign neoplasia. Turkish Journal of Cancer 1999; 29:110-18
  6. Harbeck HT, Mentlein R. Aminopeptidase P from rat brain. Eur J Biochem 1991;198:451-8
  7. Karna E, Miltyk W, Palka JA, et al. Prolidase activity and beta 1 integrin expression in moderately and poorly differentiated lung adenocarcinomas. Rocz Akad Med Bialymst 1997;42:241-50 8. Karna E, Palka JA, Chyczewski L, et al. Prolidase and prolinase activities in moderately and poorly differentiated lung adenocarcinomas. Rocz Akad Med Bialymst. 1997; 42 (1 Suppl): 230- 40
  8. Lin SB. Do overexpressed oncoproteins cause malignant growth of cancer cells-Studied by antisense oligonucleotides. Clin Chem Lab Med.l998;36:541-4
  9. Masuda S, Watanabe H, Morioka M, et al. Characteristics of partially purified prolidase and prolinase from the human prostate. Acta Med Okayama 1994;48:173-9
  10. Miltyk W, Karna E, Wolczynski S, et al. Insulin-like growth factor I dependent regulation of prolidase activity in cultured human skin fibroblasts. Mol Cell Biochem 1998; 189:177-83 12. Palka JA, Phang JM. Prolidase activity in fibroblastsis regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem. 1997; 67: 166-75
  11. Palka JA, Phang JM. Prolidase in human breast cancer MCF-7 cells. Cancer Lett. 1998;127:63-70
  12. Vanhoof G, Goossens F, De-Meester I, et al. Proline motifs in peptides and their biological processing. FASEB J 1995;9:736-44.